Stockscreener 앱 받기
517.71
1.54%
-8.11
시간 외 거래:
517.71
전일 마감가:
$525.82
열려 있는:
$525.84
하루 거래량:
401.99K
Relative Volume:
0.92
시가총액:
$25.78B
수익:
$3.17B
순이익/손실:
$1.29B
주가수익비율:
19.11
EPS:
27.0947
순현금흐름:
$1.01B
1주 성능:
-2.04%
1개월 성능:
-4.45%
6개월 성능:
+10.27%
1년 성능:
+88.46%
1일 변동 폭
$514.34
$525.84
1주일 범위
$514.34
$535.22
52주 변동 폭
$283.01
$609.35
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
United Therapeutics Corp (UTHR) Valuation: PE, PB & Fair Value Analysis - TradingKey
United Therapeutics CEO Rothblatt sells $5 million in shares - Investing.com
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
Form 4 United Therapeutics Corporation For: 27 July By Investing.com - Investing.com Canada
United Therapeutics CEO Rothblatt sells $5.05 million in stock - Investing.com
United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise - Stock Titan
United Therapeutics Corporation (UTHR) Stock Analysis: A Healthier Future with 25.5% Potential Upside - DirectorsTalk Interviews
United Therapeutics Corp (UTHR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
UTHR|United Therapeutics Corp|Price:528.470|Chg%:-1.060 - TradingKey
United Therapeutics Corp (NASDAQ: UTHR) CEO trades 9,500 shares in 10b5-1 plan - Stock Titan
United Therapeutics Corp. (UTHR) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Form 4 United Therapeutics Corporation For: 24 July By Investing.com - Investing.com South Africa
United Therapeutics Corp. (UTHR) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
United Therapeutics Director Christopher Patusky Awarded Stock Options and Common Shares in Annual Equity Grant - Kalkine Media
United Therapeutics Director Christopher Causey Awarded Stock Options and Common Shares in Annual Equity Compensation - Kalkine Media
United Therapeutics Director Louis Sullivan Updates Stock Holdings and Receives Annual Stock Option Grant - Kalkine Media
United Therapeutics Corp. (UTHR) Earnings Dates, Call Summary & Reports - TipRanks
Form 4 United Therapeutics Corporation For: 23 July By Investing.com - Investing.com South Africa
Form 4 United Therapeutics Corporation For: 23 July - Investing.com India
United Therapeutics CEO Rothblatt sells $5 million in shares By Investing.com - Investing.com Canada
United Therapeutics Corporation (UTHR) Stock Price, News, Quote & History - Yahoo! Finance Canada
United Therapeutics (UTHR) grants director Victor Dzau RSUs and stock options - Stock Titan
United Therapeutics (UTHR) director Victor Dzau submits initial Form 3 - Stock Titan
United Therapeutics (UTHR) awards RSUs and stock options to director - Stock Titan
United Therapeutics Corp (UTHR) awards RSUs and options to director - Stock Titan
United Therapeutics (UTHR) awards director 760 restricted stock units - Stock Titan
United Therapeutics (UTHR) awards 760 RSUs to board director Judy D. Olian - Stock Titan
United Therapeutics (UTHR) director gets RSU and stock option grants - Stock Titan
United Therapeutics (UTHR) awards RSUs and stock options to director Nilda Mesa - Stock Titan
United Therapeutics (UTHR) grants director 2,380 stock options at $527.07 - Stock Titan
United Therapeutics (UTHR) awards 2,380 stock options to director Causey - Stock Titan
United Therapeutics (UTHR) awards 2,380 stock options to board director - Stock Titan
United Therapeutics (UTHR) awards 760 RSUs in annual director grant - Stock Titan
United Therapeutics (NASDAQ: UTHR) grants stock units and options to director Kurzweil - Stock Titan
United Therapeutics Corp (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
United Therapeutics Boosts Board to 13 Members with Appointment of Esteemed Medical Expert Victor Dzau, M.D. - Kalkine Media
United Therapeutics (NASDAQ: UTHR) appoints Victor Dzau to board - Stock Titan
After 12 years as NAM president, Victor Dzau joins United Therapeutics board - Stock Titan
United Therapeutics Corp. (UTH) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
United Therapeutics to report Q2 2026 results on August 5 - scanx.trade
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026 - Yahoo Finance
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
Form 4 United Therapeutics Corporation For: 21 July By Investing.com - Investing.com South Africa
United Therapeutics CEO Rothblatt sells $5.05m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.05m in stock - Investing.com
United Therapeutics (UTHR) CEO executes 9,500-share option exercise and sale - Stock Titan
Boehringer Alleges United Therapeutics Poached Staff, Secrets - Law360
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
Lobbying Update: $80,000 of UNITED THERAPEUTICS CORPORATION lobbying was just disclosed - Quiver Quantitative
United Therapeutics Corp (UTHR) - MSN
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 30 '26 |
Sale |
524.90 |
9,500 |
4,986,594 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 29 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 29 '26 |
Sale |
522.37 |
9,500 |
4,962,488 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 28 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 28 '26 |
Sale |
526.73 |
9,500 |
5,003,976 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 27 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 27 '26 |
Sale |
530.42 |
9,500 |
5,038,971 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 24 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 24 '26 |
Sale |
531.74 |
9,500 |
5,051,519 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 23 '26 |
Option Exercise |
135.42 |
9,500 |
1,286,490 |
333,943 |
1.13%
1.64%
자본화:
|
볼륨(24시간):